Nav: Home

Current Evolocumab News and Events

Current Evolocumab News and Events, Evolocumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 1 | 32 Results
PCSK9 inhibitors: Specific studies are mandatory to prove efficacy and safety in CKD
High cardiovascular morbidity and mortality remains a persisting problem in patients with CKDPCSK9 inhibition represents a novel and successful treatment approach to reduce LDL-C in patients with normal to moderately impaired kidney function. (2019-06-13)
Role of PCSK9 inhibitors in high risk patients with dyslipidemia
The purpose of this review is to present available data on the efficacy and safety of the two available PCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs.A comprehensive literature search was performed to identify available data from clinical studies evaluating the impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH. (2019-01-01)
Increasing statins dose and patient adherence could save more lives
Thousands of heart attacks and deaths from cardiovascular disease could be prevented by patients taking higher doses of statins and taking the drugs as advised by doctors. (2018-12-07)
Patients with high lipoprotein(a) levels may benefit from taking PCSK9 inhibitors
In the latest analysis from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial, researchers found that PCSK9 inhibitors reduced lipoprotein(a) levels and that patients starting with higher Lp(a) levels appeared to derive greater absolute benefit from taking PSCK9 inhibitors. (2018-05-21)
PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease
A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease. (2017-11-13)
Less than half of patients prescribed new cholesterol drug receive insurance approval
In the largest study of its kind, less than half of patients prescribed the new class of cholesterol drugs, PCSK9 inhibitors, received insurance approval even if patients had atherosclerotic cardiovascular disease (plaque build-up of the arteries) or markedly elevated bad cholesterol. (2017-10-30)
High rate of prescriptions for new cholesterol medications never filled
In the first year of availability of the cholesterol lowering medications PCSK9 inhibitors, fewer than 1 in 3 adults initially prescribed one of these inhibitors actually received it, owing to a combination of out-of-pocket costs and lack of insurance approval, according to a study published by JAMA Cardiology. (2017-09-27)
Landmark findings to be presented by Brigham and Women's experts at ESC Congress 2017
Beginning Saturday, Aug. 26, Brigham and Women's Hospital cardiologists and researchers will be presenting at the ESC Congress 2017, organized by the European Society of Cardiology. (2017-08-29)
How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events. (2017-08-28)
New analysis examines how low cholesterol can safely go (FOURIER)
Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively fewer cardiovascular events and appears to pose no safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the FOURIER trial. (2017-08-28)
Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater price reductions than previously estimated may be needed to meet cost-effectiveness thresholds, according to a study published by JAMA. (2017-08-22)
No evidence of cognitive issues when evolocumab added to statin therapy
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other problems with cognition or thinking, according to findings from the EBBINGHAUS study, the largest, most rigorously designed study to address this issue to date. (2017-03-18)
PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function
New research led by the TIMI Study Group at Brigham and Women's Hospital in collaboration with Brown University and the University of Geneva reassuringly finds no association between the use of the PCSK9 inhibitor evolocumab and a decline in memory or cognitive function. (2017-03-18)
PCSK9 inhibitior bococizumab produces varying results
Researchers report that bococizumab had short-term benefits on lowering cholesterol levels and significantly reduced the risk of cardiovascular events by 21 percent compared to placebo among those who had baseline LDL cholesterol levels of greater than 100 mg/dL. (2017-03-17)
PCSK9 inhibitor evolocumab reduces adverse cardiovascular events
Patients treated with evolocumab had a 15 percent reduction in the risk of major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization Evolocumab reduced the more serious key secondary endpoint, which was a composite of heart attack, stroke or cardiovascular death, by 20 percent. (2017-03-17)
Evolocumab significantly reduces risk of cardiovascular events
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or 'bad' cholesterol, also significantly lowers the risk of cardiovascular events in patients with existing heart or vascular disease already on statin therapy, according to research presented at the American College of Cardiology's 66th Annual Scientific Session. (2017-03-17)
Study suggests new drug alongside statins can significantly cut cholesterol
A new class of cholesterol-lowering drug has been found to help patients cut their risk of cardiovascular disease, stroke and heart attack. (2017-03-17)
Canadian Cardiovascular Society sets new guidelines for management of lipid metabolism disorders that affect cholesterol and cause atherosclerosis
The Canadian Cardiovascular Society has published an important update to its guidelines for the management of dyslipidemia -- lipid metabolism disorders -- that can cause cardiovascular disease. (2016-10-11)
Recently approved cholesterol medication not cost-effective; could substantially increase US health costs
Although the recently FDA-approved cholesterol-lowering drugs, PCSK9 inhibitors, could substantially reduce heart attacks, strokes, and cardiovascular deaths, they would not be cost-effective for use in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, with annual drug prices needing to be reduced by more than two-thirds to meet a generally acceptable threshold for cost-effectiveness, according to a study appearing in the Aug. (2016-08-16)
New lipid-lowering drugs help patients reduce LDL cholesterol
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels. (2016-08-01)
Statin intolerance objectively identified in patients
In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients. (2016-04-03)
Trial offers objective evidence of muscle-related side effects with statins
The first major clinical trial to include a blinded, placebo-controlled 'statin re-challenge' in patients with a history of muscle-related side effects sheds new light on statin-associated muscle symptoms, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. (2016-04-03)
Cholesterol lowering therapies for patients with muscle-related statin intolerance
Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. (2016-04-03)
Alirocumab in hypercholesterolaemia or mixed dyslipidaemia: Added benefit not proven
None of the studies cited in the dossier is suitable for answering the research questions -- among other things, the study durations were too short for a chronic disease. (2016-02-17)
Evolocumab: No hint of added benefit
The manufacturer dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. (2015-12-22)
New vaccine could prevent high cholesterol
A new cholesterol-lowering vaccine leads to reductions in 'bad' LDL cholesterol in mice and macaques, according to research published in Vaccine. (2015-11-10)
After 1 year, patients on new drug fare better than standard therapy
Patients taking evolocumab -- an investigational therapy previously shown to dramatically lower 'bad' cholesterol -- were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to research presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego. (2015-03-15)
Journal of the American College of Cardiology notes most accessed papers
A blood test to rule out heart attack, an advisory about guidelines for preventing high blood pressure, cutting edge research on a new class of cholesterol drugs, and a study that found benefits in early surgery for mitral regurgitation were among the top accessed research studies in the Journal of the American College of Cardiology in 2014. (2014-12-22)
The Lancet: New drug achieves significant additional cholesterol-lowering in people with inherited high cholesterol on statins
Evolocumab, an injected form of a new class of drugs called PCSK9 inhibitors, is highly effective at reducing low-density lipoprotein or 'bad cholesterol' levels with few side effects in people with familial hypercholesterolaemia, an inherited condition that causes extremely high cholesterol and high risk of cardiovascular disease at an early age. (2014-10-01)
Antibody combined with statin results in further reduction of cholesterol levels
Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition of the human monoclonal antibody evolocumab resulted in additional lowering of low-density lipoprotein cholesterol levels, according to a study in the May 14 issue of JAMA. (2014-05-13)
Evolocumab safely drops LDL cholesterol well below statin-only baseline
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the (2014-03-30)
Evolocumab superior to ezetimibe in lowering LDL cholesterol
Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or 'bad cholesterol,' outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session. (2014-03-30)
Page 1 of 1 | 32 Results
   First   Previous   Next      Last   

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...